Wolfram, C.; Pfeiffer, N.; Hudde, T.; Klatt, A.; Schnegelsberg, B.; Ross, M.; Ziemssen, F.; Schuster, A.K. The Psychological, Social and Behavioral Impact of Intravitreal Anti-VEGF Therapy: An Analysis from the ALBATROS Data. J. Clin. Med.2023, 12, 7435.
Wolfram, C.; Pfeiffer, N.; Hudde, T.; Klatt, A.; Schnegelsberg, B.; Ross, M.; Ziemssen, F.; Schuster, A.K. The Psychological, Social and Behavioral Impact of Intravitreal Anti-VEGF Therapy: An Analysis from the ALBATROS Data. J. Clin. Med. 2023, 12, 7435.
Wolfram, C.; Pfeiffer, N.; Hudde, T.; Klatt, A.; Schnegelsberg, B.; Ross, M.; Ziemssen, F.; Schuster, A.K. The Psychological, Social and Behavioral Impact of Intravitreal Anti-VEGF Therapy: An Analysis from the ALBATROS Data. J. Clin. Med.2023, 12, 7435.
Wolfram, C.; Pfeiffer, N.; Hudde, T.; Klatt, A.; Schnegelsberg, B.; Ross, M.; Ziemssen, F.; Schuster, A.K. The Psychological, Social and Behavioral Impact of Intravitreal Anti-VEGF Therapy: An Analysis from the ALBATROS Data. J. Clin. Med. 2023, 12, 7435.
Abstract
Background: Retinal diseases such as neovascular age related macular degeneration (nAMD), diabetic macular edema (DME) or branch-/central retinal vein occlusion (B/CRVO) have significant implications for patients' social and psychological well-being. To gain a comprehensive understanding of patients' backgrounds and attitudes, we developed an exploratory questionnaire, the Basic Care and Patient Satisfaction Questionnaire (BPZ-9).
Methods: The ALBATROS study aimed to assess the care situation of treatment-naïve patients diagnosed with either nAMD, DME or B/CRVO. The data collection took place at the beginning of treatment and after twelve months of anti-VEGF (vascular endothelial growth factor) therapy. The BPZ-9 instrument comprises nine questions to evaluate patients’ psychological and social situation and their satisfaction with treatment.
Results: Data were collected from 1.478 nAMD (mean 78 years), 445 DME (67 years), 233 BRVO (70 years) and 144 CRVO (71 years) patients at 102 study centers throughout Germany. Approximately one third of the patients was living alone and six percent were in organized care. One in four patients had difficulties to walk and one in five needed accompany for treatment. Anxiety to lose vision was present in three out of four patients at the beginning and slightly decreased to two out of three over the 12-month treatment preriod. The distress of having a retinal disease was generally higher than the distress related to treatment. Most patients reported high treatment satisfaction (73%) and felt well informed (81%).
Conclusion: Patients receiving anti-VEGF therapy commonly experience impaired mobility, dependency on others, distress and the fear of vision loss.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
